Global Neoantigen Cancer Vaccine Market is Projected to Reach $1826.1 Million by End of the Forecast Period, 2030 -

The "Global Neoantigen Cancer Vaccine Market : Focus on Application, Approach, Type, Line of Therapy, Treatment Strategy, Country Data (15 Countries),and Competitive Landscape - Analysis and Forecast, 2023-2030" report has been added to's offering.

Key Questions Answered in this Report:

  • What are the major market drivers, challenges, and opportunities in the global neoantigen cancer vaccine market?
  • What are the underlying structures resulting in the emerging trends within the global neoantigen cancer vaccine market?
  • How is each segment expected to grow in the global neoantigen cancer vaccine market during the forecast period and what is the estimated revenue to be generated by each of the segments by the end of 2030?
  • What are the key developmental strategies which are implemented by the major players in order to sustain in the competitive market? What are the expected key regulatory implications in the developed and developing regions for the neoantigen cancer vaccines?
  • Who are the leading players with significant offerings to the global neoantigen cancer vaccine market? What is the expected market dominance for each of these leading players?
  • What is the expected compound growth rate to be witnessed by the leading players in the market during the forecast period 2023-2030?
  • What are the key applications in global neoantigen cancer vaccine market? What are the major segments of these applications?
  • Which are the dominant disease types to which the global neoantigen cancer vaccine market caters? Which oncology specialty is expected to hold the maximum market share during the forecast period (2023-2030) ?
  • What is the scope of the global neoantigen cancer vaccine market in North America, Europe, Asia-Pacific, and Rest-of-the-World?

Global Neoantigen Cancer Vaccine Market Forecast, 2023-2030

The global neoantigen cancer vaccine industry analysis projects the market to grow at a significant CAGR of 34.69% during the forecast period, 2023-2030. The neoantigen cancer vaccine market is expected to generate $227.1 million revenue in 2023, owing to the expected launch of first neoantigen vaccine Tedopi in the market.

The neoantigen cancer vaccine market growth has been primarily attributed to the major drivers in this market such as rising prevalence of cancers, increase in adoption of personalized medicine to tailor patient's treatment on an individual level, and significant external funding for executing research and development exercise. However, there are significant challenges which are restraining the market growth. These challenges include expected higher cost of personalized cancer vaccines, hurdles in clinical development, and payer uncertainty and outcome-based pricing.

Scope of the Market Intelligence on Neoantigen Cancer Vaccine Market

The neoantigen cancer vaccine market report provides a holistic view of the market in terms of various factors influencing it, including reported clinical findings, financing and partnership opportunities, expected market and current clinical landscape.

The scope of this report is centered upon conducting a detailed study of the products expected to be allied with the oncology market. In addition, the study also includes exhaustive information on the unmet needs, perception on the new products, competitive landscape, market share of key players, growth potential of each underlying sub-segment, and company, as well as other vital information with respect to the global neoantigen cancer vaccine market.

Key Topics Covered:

Executive Summary

1 Product Definition

1.1 Inclusion and Exclusion

2 Research Scope

2.1 Scope of the Study

2.2 Key Questions Answered in the Report

3 Research Methodology

3.1 Data Sources

3.2 Market Estimation Model

4 Neoantigen Vaccines in Cancer Immunotherapy: Overview

4.1 Introduction

4.2 Cancer Antigens

4.3 Targeting Cancer Neoantigen: A next wave of innovation in Oncology?

4.4 Neoantigen Cancer Vaccine Mechanism of Action

4.5 Types of Neoantigen Cancer Vaccines, by Product Type

4.6 Types of Neoantigen Cancer Vaccine Market, by Neovaccine Types (Biological Platform)

4.7 Types of Neoantigen Cancer Vaccine, by Delivery Strategies

4.8 Prediction Software for Neoantigens

4.9 Limitations of Neoantigen Cancer Vaccines

4.10 Future Prospects

5 Legal Requirements and Regulations

5.1 Overview of Regulatory Pathway for Neoantigen Cancer Vaccines

5.2 Regulatory Challenges

5.3 Successful Regulatory Strategies

6 Market Landscape

6.1 Growth Share Analysis

6.2 FDA Review Landscape

6.3 Patent Landscape

7 Market Dynamics

7.1 Overview

7.2 Emerging and Current Market Trends

7.3 Market Drivers

7.4 Market Restraints

7.5 Market Opportunities

8 Pipeline Landscape

8.1 Emerging Neoantigen Vaccines

8.2 Clinical Trials Heat Map

8.3 Pipeline Analysis

9 Competitive Landscape

9.1 Key Strategies and Developments

9.2 Partnership and Financing Opportunities

10 Global Neoantigen Cancer Vaccine Market by Product Type, 2023-2030

10.1 Personalized Neoantigen Vaccines

10.2 Off-the-Shelf Neoantigen Vaccines

11 Global Neoantigen Cancer Vaccine Market by Type of Neovaccine, 2023-2030

11.1 Nucleic Acid/DNA/mRNA Vaccines

11.2 RNA Vaccines

11.3 Peptide Vaccines

11.4 Dendritic Cell-Based Vaccines

12 Global Neoantigen Cancer Vaccine Market by Line of Therapy, 2023-2030

12.1 First Line Neovaccines Regimens

12.2 Second Line Neovaccine Regimens

12.3 Later Lines Neovaccines Regimens

13 Global Neoantigen Cancer Vaccine Market by Therapy Type, 2023-2030

13.1 Mono Therapeutic Regimens

13.2 Combinatorial Regimens

14 Global Neoantigen Cancer Vaccine Market by Therapeutic Specialty, 2023-2030

14.1 Hematological Malignancies

14.2 Melanoma

14.3 Breast Cancer

14.4 Gastrointestinal Cancer

14.5 Lung Cancer

14.6 Solid Tumors

14.7 Urinary System Cancer

14.8 Prostate Cancer

14.9 Head and Neck Cancers

14.10 Gynecologic Cancers

14.11 Brain Cancer

15 Global Neoantigen Cancer Vaccine Market by Region, 2023-2030

15.1 Overview

15.2 North America

15.3 Canada

15.4 Europe

15.5 Asia-Pacific

16 Company Profiles

16.1 Moderna Therapeutics

16.2 F. Hoffmann-La Roche Ltd

16.3 AstraZeneca plc

16.4 Agenus

16.5 OSE Immunotherapeutics

16.6 Advaxis

16.7 Medigene

16.8 Neon Therapeutics

16.9 Genocea Biosciences

16.10 Immunovative Therapies

16.11 Gritstone Oncology

16.12 Nouscom

16.13 NantBioScience

16.14 Immunovaccine

16.15 BioLineRx

17 Anticipated Milestones

For more information about this report visit

View source version on

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900